Pfizer has an extensive history of high dividend yield: 5.73% TTM, up significantly since the sharp 2020-2021 decline--payout ratio 90.08%. However, a significant decline in earnings is tied directly to a share price decline. Unsure if recovery is expected, good horizons: approval in EU (small) } Bad horizons: Pfizer's uncontested market share/exclusivity decline, lack of meaningful pipeline, . Can we expect a dividend increase?